PRCT
PROCEPT BioRobotics Corporation+$0.73 (3.76%) At close $20.17 · Tue
☾After Hours −$0.32 (1.60%) Nov 3, 7:59 PM ET
About PRCT
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
Company
- Headquarters
- San Jose, CA
- Employees
- 888 (2026)
- Listed
- Sep 15, 2021
- Exchange
- Nasdaq
- Website
- procept-biorobotics.com
- SEC industry
- Surgical & Medical Instruments & Apparatus
- Cylvex sector
- Health Care · Medical Devices
Medical Devices
- Market cap #53 of 163
- P/B #80 of 152
Ranked highest first among stocks Cylvex covers.
- ABTAbbott Laboratories$189.3B-0.69%
- ISRGIntuitive Surgical Inc$155.7B+0.89%
- MDTMedtronic plc$126.5B-0.41%
- SYKStryker Corporation$119.1B+1.22%
- BSXBoston Scientific Corp.$63.04B-1.85%
Financial summary
Related companies
About
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
From company filings and market data · Not investment advice
Price data
52W range and average volume from daily bars (unadjusted, last 252 sessions).
Financials
Consensus estimates
The information provided is for educational purposes only and does not constitute investment advice. Past performance does not guarantee future results.